Virus-Like Particles (VLPs): A Trend Report
San Jose, California (PRWEB) January 23, 2014
Virus-like particles (VLPs) bear high structural resemblance to viruses, though completely non-infectious in nature due to the absence of viral genetic material. Despite lacking DNA material, VLPs retain key immunological characteristics of viruses, including particulate structures; repetitive surfaces; and capability to induce innate immunity by activating molecular-pattern pathogen-associated recognition receptors. Technological advancements in vaccine development are fuelling demand for VLPs. VLPs are rapidly emerging as a promising vaccine technology to develop therapies capable of delivering long-lasting and more effective protection against infectious diseases.
The trend report titled “Virus-Like Particles (VLPs)” announced by Global Industry Analysts Inc., is a focused research paper which provides cursory insights into the product, applications, future prospects and corporate initiatives of key companies worldwide. Also covered are companies such as Cytos Biotechnology AG, Icosagen AS, Medicago Inc., Medigene AG, Novavax Inc., Oxford Expression Technologies Ltd., Paragon Bioservices Inc., Redbiotec AG, Virometix AG, and VLPbio - The Vaccines Company, among others.
For more details about this trend report, please visit http://www.strategyr.com/TrendReport.asp?code=146284
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.